Investors & Media

Press Releases



All Releases
View Summary TG Therapeutics Announces Orphan Drug Designation for the Combination of TG-1101 and TGR-1202 for the Treatment of Diffuse Large B-cell Lymphoma
Jan 24, 2017
PDF 282.4 KB Add to Briefcase
View Summary TG Therapeutics Announces Completion of Enrollment and B-cell Depletion Data from Part 1 of Ongoing Phase 2 Multiple Sclerosis Study
Jan 11, 2017
PDF 282.5 KB Add to Briefcase
View Summary TG Therapeutics Announces Orphan Drug Designation for the Combination of TG-1101 and TGR-1202 for Treatment of Chronic Lymphocytic Leukemia
Jan 9, 2017
PDF 281.9 KB Add to Briefcase
View Summary TG Therapeutics, Inc. to Present at the 35th Annual J.P. Morgan Healthcare Conference
Jan 9, 2017
PDF 278.1 KB Add to Briefcase
View Summary TG Therapeutics, Inc. Announces Investigator Initiated Trial at the University of Nebraska Medical Center to Study TGR-1202 in Combination with Ibrutinib in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma
Jan 4, 2017
PDF 283.5 KB Add to Briefcase
View Summary TG Therapeutics, Inc. Announces Publication of Clinical Data from the Phase 2 Trial of TG-1101 (ublituximab) in Combination with Ibrutinib in the British Journal of Haematology
Dec 16, 2016
PDF 283.3 KB Add to Briefcase
View Summary TG Therapeutics, Inc. Announces Double & Triple Combination Therapy Data Presentations at the 58th American Society of Hematology Annual Meeting
Dec 6, 2016
PDF 320.1 KB Add to Briefcase
View Summary TG Therapeutics, Inc. Announces that the GENUINE Phase 3 Study has Reached Target Enrollment
Dec 6, 2016
PDF 281.7 KB Add to Briefcase
View Summary TG Therapeutics, Inc. Announces Oral Data Presentation for TGR-1202 in Combination with Ibrutinib in Patients with Relapsed or Refractory CLL or MCL at the 58th American Society of Hematology Annual Meeting
Dec 5, 2016
PDF 287.8 KB Add to Briefcase
View Summary TG Therapeutics, Inc. Announces Preclinical Data Presentations for TGR-1202 at the 58th American Society of Hematology Annual Meeting
Dec 5, 2016
PDF 288.4 KB Add to Briefcase
View Summary TG Therapeutics, Inc. Recaps Schedule of Data Presentations at the 58th American Society of Hematology Annual Meeting
Dec 2, 2016
PDF 327.5 KB Add to Briefcase
View Summary TG Therapeutics Announces Positive DSMB Recommendation for Continuation of the UNITY-CLL Phase 3 Trial
Nov 22, 2016
PDF 282.0 KB Add to Briefcase
View Summary TG Therapeutics, Inc. Provides Business Update and Reports Third Quarter 2016 Financial Results
Nov 7, 2016
PDF 298.1 KB Add to Briefcase
View Summary TG Therapeutics, Inc. to Host Conference Call on Third Quarter 2016 Financial Results and Business Update
Nov 3, 2016
PDF 278.9 KB Add to Briefcase
View Summary TG Therapeutics, Inc. Announces Data Presentations at the Upcoming 58th American Society of Hematology Annual Meeting
Nov 3, 2016
PDF 328.2 KB Add to Briefcase
View Summary TG Therapeutics, Inc. Announces Publication in Blood Describing a Novel Complimentary Mechanism of the PI3K-delta Inhibitor, TGR-1202
Oct 27, 2016
PDF 284.2 KB Add to Briefcase
View Summary TG Therapeutics, Inc. Announces the Launch of the Phase 1/2 Study of TGR-1202 and Carfilzomib in Patients with Relapsed or Refractory Lymphoma
Oct 20, 2016
PDF 283.4 KB Add to Briefcase
View Summary TG Therapeutics, Inc. Amends the GENUINE Phase 3 Clinical Trial to Accelerate Study Completion by Revising Primary Endpoint to Overall Response Rate
Oct 13, 2016
PDF 287.6 KB Add to Briefcase
View Summary TG Therapeutics, Inc. to Host Conference Call to Provide an Update on the GENUINE Phase 3 Trial
Oct 12, 2016
PDF 279.0 KB Add to Briefcase
View Summary TG Therapeutics, Inc. to Present at the Ladenburg Thalmann 2016 Healthcare Conference
Sep 23, 2016
PDF 279.1 KB Add to Briefcase
Showing 21-40 of 183 Page: 1 2 3 4 5 6 ... 10  Previous 20 | Next 20
Add to Briefcase = add release to Briefcase